Sanofi, Regeneron halt Phase 3 Dupixent trial due to lack of efficacy
In the interim analysis, Dupixent showed positive results in reducing itch and hives (primary endpoints) but did not…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Feb 22
In the interim analysis, Dupixent showed positive results in reducing itch and hives (primary endpoints) but did not…
14 Feb 22
We focus on how adaptive trial designs have enabled clinical research, which could lower overall drug development costs…
07 Feb 22
A look at how Covid-19 has led to more complexity in the sourcing of ancillary supplies and what…
31 Jan 22
We focus on the challenges facing those running clinical trials and how technology could be used to help…
21 Jan 22
People who received two doses of Sputnik V showed high levels of antibodies against Omicron than those vaccinated…
19 Jan 22
The combination also showed no increase in severe liver toxicity and fewer discontinuations due to treatment-related adverse events…
13 Jan 22
In the Phase 3 study, PREVNAR 20 vaccine triggered similar responses for all 20 serotypes, either with Pfizer-BioNTech…
08 Dec 21
The vaccine showed 71% overall efficacy against all variants of SARS-COV-2, and 75.6% in people who were not…
16 Nov 21
AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A), jointly developed by AstraZeneca and…
12 Nov 21
The 77.8% vaccine efficacy was based on 130 confirmed cases, where 24 cases were observed in the vaccine…